Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Cortical Lesions in Primary Progressive Multiple Sclerosis: A 2-Year Longitudinal MR Study
Neurol 72:1330-1336, Calabrese,M.,et al, 2009
Hippocampal Lesion Patterns in Acute Posterior Cerebral Artery Stroke: Clinical and MRI Findings
Stroke 40:2042-2045, Szabo,K.,et al, 2009
Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
Neuromyelitis Optica and Concentric Rings of Bal� in the Brainstem
Arch Neurol 66:274-275, Graber,J.J.,et al, 2009
Incidental MRI Anomalies Suggestive of Multiple Sclerosis: The Radiologically Isolated Syndrome
Neurol 72:800-805,780, Okuda,D.T.,et al, 2009
Posterior Reversible Encephalopathy Syndrome in Neuromyelitis Optica Spectrum Disorders
Neurol 72:712-717, Maga�a,S.M.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study
Arch Neurol 66:1345-1352, Moraal,B.,et al, 2009
Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009
Non-Communicating Syringomyelia: A Feature of Spinal Cord Involvement in Multiple Sclerosis
Brain 131:1776-1782, Weier,K.,et al, 2008
Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging
Semin Neurol 28:453-466, Fox,R.J., 2008
Treatment of Neuromyelitis Optica with Rituximab; Retrospective Analysis of 25 Patients
Arch Neurol 65:1443-1448, Jacob,A.,et al, 2008
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Stroke and Multi-Infarct Dementia as Presenting Symptoms of Giant Cell Arteritis: Report of 7 Cases and Review of the Literature
Medicine 87:335-344, Solans-Laque,R.,et al, 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Curable Cause of Paraplegia: Spinal Dural Arteriovenous Fistulae
Stroke 39:2756-2759, Aghakhani,N.,et al, 2008
Intracranial Hemorrhage in Children
Arch Neurol 65:1629-1633, Lo,W.D.,et al, 2008
Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008
Gray Matter Atrophy in Multiple Sclerosis: A Longitudinal Study
Ann Neurol 64:255-265,230, Fisher,E.,et al, 2008
Bal�s Disease Showing Benign Clinical Course and Co-Existence with Multiple Sclerosis-Like Lesions in Chinese
Multiple Sclerosis 14:418-424, Wang,C.,et al, 2008
Mitoxantrone as Induction Treatment in aggressive Relapsing Remitting Multiple Sclerosis: Treatment Response Factors in a 5 Year Follow-up Observational Study of 100 Consecutive Patients
JNNP 79:52-56, Le Page,E.,et al, 2008
Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
NEJM 358:647-648, Mullen,J.T.,et al, 2008
Finding NMO: Neuromyelitis Optica in Chidlren
Neurol 70:334-335, Levy,M.,et al, 2008
Unexpected Multiple Sclerosis: Follow-Up of 30 Patients With Magnetic Resonance Imaging and Clinical Conversion Profile
JNNP 79:195-198,112, Lebrun,C.,et al, 2008
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Do Oligoclonal Bands Add Information to MRI in First Attacks of Multiple Sclerosis?
Neurol 70:1079-1083,1059, Tintore,M.,et al, 2008
Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Prediction of Functional Outcome in Patients With Primary Intracerebral Hemorrhage: The FUNC Score
Stroke 39:2304-2309, Rost,N.S.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008
NMO Antibody-Positive Recurrent Optic Neuritis Without Clear Evidence of Transverse Myelitis
Arch Ophthalmol 126:566-570, Dinkin,M.J.,et al, 2008
Neurologic Manifestations of Localized Scleroderma: A Case Report and Literature Review
Neurol 71:1538-1545, Kister,I.,et al, 2008
Efficacy and Safety of Oral Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase LLB Study
Lancet 372:1463-1472, Kappos,L.,et al, 2008
Multiple Sclerosis
Lancet 372:1502-1517, Compston,A. &Coles,A., 2008
Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Percutaneous Clot Removal Devices in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Arch Neurol 65:1024-1030, Stead,L.G.,et al., 2008
Four New Cases of Therapy-Related Acute Promyelocytic Leukemia After Mitoxantrone
Neurol 71:457-458, Bosca,I.,et al., 2008
Mlutiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-Up
Arch Neurol 65:727-732, The Optic Neuritis Study Group, 2008
Hyperdense Internal Carotid Artery Sign: A CT Sign of Acute Ischemia
Stroke 39:2011-2016, Ozdemir,O.,et al, 2008
Effect of Laquinimod on MRI-Monitored Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study
Lancet 371:2085-2092,2059, Comi,G.,etc., 2008
NMO-IgG Predicts the Outcome of Recurrent Optic Neuritis
Neurol 70:2197-2200, Matiello,M.,et al, 2008